메뉴 건너뛰기




Volumn 1, Issue , 2010, Pages 9-22

Refining the treatment of advanced nonsmall cell lung cancer

Author keywords

Chemotherapy; Lung cancer; Targeted treatment

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; CP 751871; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX; SORAFENIB; TAXANE DERIVATIVE; VANDETANIB;

EID: 77955180842     PISSN: None     EISSN: 11792728     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (1)

References (113)
  • 2
    • 0031861215 scopus 로고    scopus 로고
    • Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
    • Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998;16(7):2459-2465.
    • (1998) J Clin Oncol , vol.16 , Issue.7 , pp. 2459-2465
    • Wozniak, A.J.1    Crowley, J.J.2    Balcerzak, S.P.3
  • 3
    • 0033950286 scopus 로고    scopus 로고
    • Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
    • Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000;18(3):623-631.
    • (2000) J Clin Oncol , vol.18 , Issue.3 , pp. 623-631
    • Bonomi, P.1    Kim, K.2    Fairclough, D.3
  • 4
    • 0042413836 scopus 로고    scopus 로고
    • Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group
    • Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21(16):3016-3024.
    • (2003) J Clin Oncol , vol.21 , Issue.16 , pp. 3016-3024
    • Fossella, F.1    Pereira, J.R.2    von Pawel, J.3
  • 5
    • 17344384668 scopus 로고    scopus 로고
    • Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
    • Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000;18(1):122-130.
    • (2000) J Clin Oncol , vol.18 , Issue.1 , pp. 122-130
    • Sandler, A.B.1    Nemunaitis, J.2    Denham, C.3
  • 6
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer
    • Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543-3551.
    • (2008) J Clin Oncol , vol.26 , Issue.21 , pp. 3543-3551
    • Scagliotti, G.V.1    Parikh, P.2    von Pawel, J.3
  • 7
    • 6344254442 scopus 로고    scopus 로고
    • Chemotherapy versus supportive care in advanced non-small cell lung cancer: Improved survival without detriment to quality of life
    • Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax. 2004;59(10): 828-836.
    • (2004) Thorax , vol.59 , Issue.10 , pp. 828-836
    • Spiro, S.G.1    Rudd, R.M.2    Souhami, R.L.3
  • 8
    • 0028843552 scopus 로고
    • Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group
    • Non-small Cell Lung Cancer Collaborative Group
    • Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995 Oct 7;311(7010): 899-909.
    • (1995) BMJ , vol.311 , Issue.7010 , pp. 899-909
  • 9
    • 0034933050 scopus 로고    scopus 로고
    • Value and accuracy of cytology in addition to histology in the diagnosis of lung cancer at flexible bronchoscopy
    • Jones AM, Hanson IM, Armstrong GR, O'Driscoll BR. Value and accuracy of cytology in addition to histology in the diagnosis of lung cancer at flexible bronchoscopy. Respir Med. 2001;95(5):374-378.
    • (2001) Respir Med , vol.95 , Issue.5 , pp. 374-378
    • Jones, A.M.1    Hanson, I.M.2    Armstrong, G.R.3    O'Driscoll, B.R.4
  • 10
    • 0033934570 scopus 로고    scopus 로고
    • Preoperative histological classification of primary lung cancer: Accuracy of diagnosis and use of the non-small cell category
    • Edwards SL, Roberts C, McKean ME, Cockburn JS, Jeffrey RR, Kerr KM. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol. 2000;53(7):537-540.
    • (2000) J Clin Pathol , vol.53 , Issue.7 , pp. 537-540
    • Edwards, S.L.1    Roberts, C.2    McKean, M.E.3    Cockburn, J.S.4    Jeffrey, R.R.5    Kerr, K.M.6
  • 11
    • 64249102154 scopus 로고    scopus 로고
    • Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens
    • Khayyata S, Yun S, Pasha T, et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol. 2009;37(3): 178-183.
    • (2009) Diagn Cytopathol , vol.37 , Issue.3 , pp. 178-183
    • Khayyata, S.1    Yun, S.2    Pasha, T.3
  • 12
    • 0027491260 scopus 로고
    • How reliable is the diagnosis of lung cancer using small biopsy specimens? Report of a UKCCCR Lung Cancer Working Party
    • Thomas JS, Lamb D, Ashcroft T, et al. How reliable is the diagnosis of lung cancer using small biopsy specimens? Report of a UKCCCR Lung Cancer Working Party. Thorax. 1993;48(11):1135-1139.
    • (1993) Thorax , vol.48 , Issue.11 , pp. 1135-1139
    • Thomas, J.S.1    Lamb, D.2    Ashcroft, T.3
  • 13
    • 70349149267 scopus 로고    scopus 로고
    • Diagnostic reproducibility of squamous cell carcinoma (SC) in the era of histology-directed non-small cell lung cancer (NSCLC) chemotherapy: A large prospective study [abstract]
    • Grilley-Olson JE, Hayes DN, Qaqish BF, et al. Diagnostic reproducibility of squamous cell carcinoma (SC) in the era of histology-directed non-small cell lung cancer (NSCLC) chemotherapy: A large prospective study [abstract]. J Clin Oncol. 2009;27:8008.
    • (2009) J Clin Oncol , vol.27 , pp. 8008
    • Grilley-Olson, J.E.1    Hayes, D.N.2    Qaqish, B.F.3
  • 14
    • 3242803674 scopus 로고    scopus 로고
    • Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis
    • Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA. 2004;292(4):470-484.
    • (2004) JAMA , vol.292 , Issue.4 , pp. 470-484
    • Delbaldo, C.1    Michiels, S.2    Syz, N.3    Soria, J.C.4    le Chevalier, T.5    Pignon, J.P.6
  • 15
    • 0037050352 scopus 로고    scopus 로고
    • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    • Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-98.
    • (2002) N Engl J Med , vol.346 , Issue.2 , pp. 92-98
    • Schiller, J.H.1    Harrington, D.2    Belani, C.P.3
  • 16
    • 0035397994 scopus 로고    scopus 로고
    • Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial
    • Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19(13): 3210-3218.
    • (2001) J Clin Oncol , vol.19 , Issue.13 , pp. 3210-3218
    • Kelly, K.1    Crowley, J.2    Bunn Jr., P.A.3
  • 17
    • 0036810227 scopus 로고    scopus 로고
    • Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial
    • Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002;13(10):1539-1549.
    • (2002) Ann Oncol , vol.13 , Issue.10 , pp. 1539-1549
    • Rosell, R.1    Gatzemeier, U.2    Betticher, D.C.3
  • 18
    • 0036843105 scopus 로고    scopus 로고
    • Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
    • Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20(21):4285-4291.
    • (2002) J Clin Oncol , vol.20 , Issue.21 , pp. 4285-4291
    • Scagliotti, G.V.1    de Marinis, F.2    Rinaldi, M.3
  • 19
    • 33847276516 scopus 로고    scopus 로고
    • Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced nonsmall-cell lung cancer: Four-Arm Cooperative Study in Japan
    • Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced nonsmall-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007;18(2):317-323.
    • (2007) Ann Oncol , vol.18 , Issue.2 , pp. 317-323
    • Ohe, Y.1    Ohashi, Y.2    Kubota, K.3
  • 20
    • 19444365516 scopus 로고    scopus 로고
    • Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A meta-analysis of the published literature
    • D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23(13):2926-2936.
    • (2005) J Clin Oncol , vol.23 , Issue.13 , pp. 2926-2936
    • D'addario, G.1    Pintilie, M.2    Leighl, N.B.3    Feld, R.4    Cerny, T.5    Shepherd, F.A.6
  • 21
    • 37549030869 scopus 로고    scopus 로고
    • Efficacy and side effects of cisplatin and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials
    • Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer. 2008;59(1):1-11.
    • (2008) Lung Cancer , vol.59 , Issue.1 , pp. 1-11
    • Rajeswaran, A.1    Trojan, A.2    Burnand, B.3    Giannelli, M.4
  • 22
    • 33644841071 scopus 로고    scopus 로고
    • Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced nonsmall-cell lung cancer: Results of a phase II-III study
    • Paccagnella A, Oniga F, Bearz A, et al. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced nonsmall-cell lung cancer: results of a phase II-III study. J Clin Oncol. 2006;24(4):681-687.
    • (2006) J Clin Oncol , vol.24 , Issue.4 , pp. 681-687
    • Paccagnella, A.1    Oniga, F.2    Bearz, A.3
  • 23
    • 0035849269 scopus 로고    scopus 로고
    • Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial
    • Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2001;357(9267):1478-1484.
    • (2001) Lancet , vol.357 , Issue.9267 , pp. 1478-1484
    • Georgoulias, V.1    Papadakis, E.2    Alexopoulos, A.3
  • 24
    • 0041912766 scopus 로고    scopus 로고
    • Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group
    • Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21(16):3025-3034.
    • (2003) J Clin Oncol , vol.21 , Issue.16 , pp. 3025-3034
    • Gridelli, C.1    Gallo, C.2    Shepherd, F.A.3
  • 25
    • 4143146439 scopus 로고    scopus 로고
    • Front-line paclitaxelvinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: A randomized phase III trial
    • Stathopoulos GP, Veslemes M, Georgatou N, et al. Front-line paclitaxelvinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. Ann Oncol. 2004;15(7):1048-1055.
    • (2004) Ann Oncol , vol.15 , Issue.7 , pp. 1048-1055
    • Stathopoulos, G.P.1    Veslemes, M.2    Georgatou, N.3
  • 26
    • 0036729263 scopus 로고    scopus 로고
    • Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial
    • Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2002;20(17): 3578-3585.
    • (2002) J Clin Oncol , vol.20 , Issue.17 , pp. 3578-3585
    • Kosmidis, P.1    Mylonakis, N.2    Nicolaides, C.3
  • 27
    • 20944436114 scopus 로고    scopus 로고
    • Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: A phase III study addressing the case for cisplatin
    • Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol. 2005;16(4):602-610.
    • (2005) Ann Oncol , vol.16 , Issue.4 , pp. 602-610
    • Pujol, J.L.1    Breton, J.L.2    Gervais, R.3
  • 28
    • 21144437547 scopus 로고    scopus 로고
    • Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III randomized trial
    • Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2005;23(13):2937-2945.
    • (2005) J Clin Oncol , vol.23 , Issue.13 , pp. 2937-2945
    • Georgoulias, V.1    Ardavanis, A.2    Tsiafaki, X.3
  • 29
    • 2942731677 scopus 로고    scopus 로고
    • Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: From the German and Swiss Lung Cancer Study Group
    • Laack E, Dickgreber N, Müller T, et al. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004 15;22(12):2348-2356.
    • (2004) J Clin Oncol , vol.15-22 , Issue.12 , pp. 2348-2356
    • Laack, E.1    Dickgreber, N.2    Müller, T.3
  • 30
    • 33847295600 scopus 로고    scopus 로고
    • Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: A phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101)
    • Comella P, Filippelli G, De Cataldis G, et al. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol. 2007;18(2):324-330.
    • (2007) Ann Oncol , vol.18 , Issue.2 , pp. 324-330
    • Comella, P.1    Filippelli, G.2    de Cataldis, G.3
  • 31
    • 34347379142 scopus 로고    scopus 로고
    • Cisplatinversus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis
    • Ardizzoni A, Boni L, Tiseo M, et al. Cisplatinversus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99(11):847-857.
    • (2007) J Natl Cancer Inst , vol.99 , Issue.11 , pp. 847-857
    • Ardizzoni, A.1    Boni, L.2    Tiseo, M.3
  • 32
    • 2442661845 scopus 로고    scopus 로고
    • Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    • Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-1597.
    • (2004) J Clin Oncol , vol.22 , Issue.9 , pp. 1589-1597
    • Hanna, N.1    Shepherd, F.A.2    Fossella, F.V.3
  • 33
    • 64049115311 scopus 로고    scopus 로고
    • The differential efficacy of pemetrexed according to NSCLC histology: A review of two Phase III studies
    • Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist. 2009;14(3):253-263.
    • (2009) Oncologist , vol.14 , Issue.3 , pp. 253-263
    • Scagliotti, G.1    Hanna, N.2    Fossella, F.3
  • 34
    • 2942657615 scopus 로고    scopus 로고
    • Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
    • Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184-2191.
    • (2004) J Clin Oncol , vol.22 , Issue.11 , pp. 2184-2191
    • Johnson, D.H.1    Fehrenbacher, L.2    Novotny, W.F.3
  • 35
    • 0037674465 scopus 로고    scopus 로고
    • Epidermal growth factor family of receptors in preneoplasia and lung cancer: Perspectives for targeted therapies
    • Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer. 2003;41 Suppl 1:S29-S42.
    • (2003) Lung Cancer , vol.41 , Issue.SUPPL. 1
    • Hirsch, F.R.1    Scagliotti, G.V.2    Langer, C.J.3    Varella-Garcia, M.4    Franklin, W.A.5
  • 36
    • 1542503746 scopus 로고    scopus 로고
    • Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1
    • Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol. 2004;22(5):777-784.
    • (2004) J Clin Oncol , vol.22 , Issue.5 , pp. 777-784
    • Giaccone, G.1    Herbst, R.S.2    Manegold, C.3
  • 37
    • 1542713370 scopus 로고    scopus 로고
    • Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2
    • Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol. 2004;22(5):785-794.
    • (2004) J Clin Oncol , vol.22 , Issue.5 , pp. 785-794
    • Herbst, R.S.1    Giaccone, G.2    Schiller, J.H.3
  • 38
    • 24944440830 scopus 로고    scopus 로고
    • TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
    • Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(25):5892-5899.
    • (2005) J Clin Oncol , vol.23 , Issue.25 , pp. 5892-5899
    • Herbst, R.S.1    Prager, D.2    Hermann, R.3
  • 39
    • 34248140107 scopus 로고    scopus 로고
    • Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
    • Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25(12):1545-1552.
    • (2007) J Clin Oncol , vol.25 , Issue.12 , pp. 1545-1552
    • Gatzemeier, U.1    Pluzanska, A.2    Szczesna, A.3
  • 40
    • 0035155064 scopus 로고    scopus 로고
    • Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis
    • Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol. 2001;8(1):72-79.
    • (2001) Ann Surg Oncol , vol.8 , Issue.1 , pp. 72-79
    • Han, H.1    Silverman, J.F.2    Santucci, T.S.3
  • 41
    • 3242700400 scopus 로고    scopus 로고
    • The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients
    • Kaya A, Ciledag A, Gulbay BE, et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med. 2004;98(7):632-636.
    • (2004) Respir Med , vol.98 , Issue.7 , pp. 632-636
    • Kaya, A.1    Ciledag, A.2    Gulbay, B.E.3
  • 42
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 14;355(24):2542-2550.
    • (2006) N Engl J Med , vol.14-355 , Issue.24 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3    Et al.4
  • 43
    • 62449124416 scopus 로고    scopus 로고
    • Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL
    • Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol. 2009;27(8):1227-1234.
    • (2009) J Clin Oncol , vol.27 , Issue.8 , pp. 1227-1234
    • Reck, M.1    von Pawel, J.2    Zatloukal, P.3
  • 44
    • 39849111354 scopus 로고    scopus 로고
    • A randomized multicenter phase III study of cetuximab in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer
    • Lynch TJ, Patel T, Dreisbach L, et al. A randomized multicenter phase III study of cetuximab in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer. J Thorac Oncol. 2007; 2:S340.
    • (2007) J Thorac Oncol , vol.2
    • Lynch, T.J.1    Patel, T.2    Dreisbach, L.3
  • 45
    • 62549097420 scopus 로고    scopus 로고
    • Overall survival results from the phase III trial BMS 099: Cetuximab + taxane/carboplatin as 1st-line treatment for advanced NSCLC
    • Lynch TJ, Patel T, Dreisbach L, et al. Overall survival results from the phase III trial BMS 099: cetuximab + taxane/carboplatin as 1st-line treatment for advanced NSCLC. J Thorac Oncol. 2008;2:S305.
    • (2008) J Thorac Oncol , vol.2
    • Lynch, T.J.1    Patel, T.2    Dreisbach, L.3
  • 46
    • 65349116059 scopus 로고    scopus 로고
    • Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An openlabel randomised phase III trial
    • Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an openlabel randomised phase III trial. Lancet. 2009;373:1525-1531.
    • (2009) Lancet , vol.373 , pp. 1525-1531
    • Pirker, R.1    Pereira, J.R.2    Szczesna, A.3
  • 47
    • 68949124435 scopus 로고    scopus 로고
    • Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study
    • O'Byrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study. J Clin Oncol. 2009;27:S15, (abstract 8007).
    • (2009) J Clin Oncol , vol.27
    • O'Byrne, K.J.1    Bondarenko, I.2    Barrios, C.3
  • 48
    • 62549155921 scopus 로고    scopus 로고
    • K-RAS mutations (MT) and EGFR-related markers as potential predictors of cetuximab benefit in 1st line advanced NSCLC: Results from the BMS099 Study [abstract]
    • Khambata-Ford S, Harbison CT, Hart LL, et al. K-RAS mutations (MT) and EGFR-related markers as potential predictors of cetuximab benefit in 1st line advanced NSCLC: Results from the BMS099 Study [abstract]. J Thorac Oncol. 2008;3:S304-S305.
    • (2008) J Thorac Oncol , vol.3
    • Khambata-Ford, S.1    Harbison, C.T.2    Hart, L.L.3
  • 49
    • 33750207905 scopus 로고    scopus 로고
    • Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of- life benefits in advanced non-small-cell lung cancer
    • Von Plessen C, Bergman B, Andresen O, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of- life benefits in advanced non-small-cell lung cancer. Br J Cancer. 2006;95(8):966-973.
    • (2006) Br J Cancer , vol.95 , Issue.8 , pp. 966-973
    • von Plessen, C.1    Bergman, B.2    Andresen, O.3
  • 50
    • 0036499649 scopus 로고    scopus 로고
    • Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer
    • Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002;20(5):1335-1343.
    • (2002) J Clin Oncol , vol.20 , Issue.5 , pp. 1335-1343
    • Socinski, M.A.1    Schell, M.J.2    Peterman, A.3
  • 51
    • 70249130544 scopus 로고    scopus 로고
    • Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and metaanalysis of randomized trials
    • Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and metaanalysis of randomized trials. J Clin Oncol. 2009; 27(20):3277-3283.
    • (2009) J Clin Oncol , vol.27 , Issue.20 , pp. 3277-3283
    • Soon, Y.Y.1    Stockler, M.R.2    Askie, L.M.3    Boyer, M.J.4
  • 52
    • 36849019938 scopus 로고    scopus 로고
    • Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer
    • Park JO, Kim SW, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007;25(33):5233-5239.
    • (2007) J Clin Oncol , vol.25 , Issue.33 , pp. 5233-5239
    • Park, J.O.1    Kim, S.W.2    Ahn, J.S.3
  • 53
    • 42549114204 scopus 로고    scopus 로고
    • Optimal duration of chemotherapy in non-small-cell lung cancer: Multicenter, randomized, prospective clinical trial comparing 4 vs 6 cycles of carboplatin and gemcitabine
    • Suppl abstract P2-P235
    • Barata FJ, Parente B, Teixeira E, et al. Optimal duration of chemotherapy in non-small-cell lung cancer: multicenter, randomized, prospective clinical trial comparing 4 vs 6 cycles of carboplatin and gemcitabine. J Thorac Oncol. 2007;2:S666(Suppl; abstract P2-P235).
    • (2007) J Thorac Oncol , vol.2
    • Barata, F.J.1    Parente, B.2    Teixeira, E.3
  • 54
    • 33646485007 scopus 로고    scopus 로고
    • Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
    • Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006;52(2):155-163.
    • (2006) Lung Cancer , vol.52 , Issue.2 , pp. 155-163
    • Brodowicz, T.1    Krzakowski, M.2    Zwitter, M.3
  • 55
    • 59149092945 scopus 로고    scopus 로고
    • Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer
    • Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(4):591-598.
    • (2009) J Clin Oncol , vol.27 , Issue.4 , pp. 591-598
    • Fidias, P.M.1    Dakhil, S.R.2    Lyss, A.P.3
  • 56
    • 70349092474 scopus 로고    scopus 로고
    • Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)
    • Suppl abstract CRA8000
    • Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2009;27:18s(Suppl; abstract CRA8000).
    • (2009) J Clin Oncol , vol.27
    • Belani, C.P.1    Brodowicz, T.2    Ciuleanu, T.3
  • 57
    • 70349475409 scopus 로고    scopus 로고
    • SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC
    • Suppl; abstract 8001
    • Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol. 2009;27:15s(Suppl; abstract 8001).
    • (2009) J Clin Oncol , vol.27
    • Cappuzzo, F.1    Ciuleanu, T.2    Stelmakh, L.3
  • 58
    • 75649135772 scopus 로고    scopus 로고
    • Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: Results from the phase III SATURN study
    • Suppl 1; abstract A2.1
    • Cappuzzo F, Coudert BP, Wierzbicki R, et al. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study. J Thorac Oncol. 2009;4:S289 (Suppl 1; abstract A2.1).
    • (2009) J Thorac Oncol , vol.4
    • Cappuzzo, F.1    Coudert, B.P.2    Wierzbicki, R.3
  • 59
    • 70349477817 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
    • Suppl; abstract LBA8002
    • Miller VA, O'Connor P, Soh C, et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2009;27:18s(Suppl; abstract LBA8002).
    • (2009) J Clin Oncol , vol.27
    • Miller, V.A.1    O'Connor, P.2    Soh, C.3
  • 60
    • 0034069620 scopus 로고    scopus 로고
    • Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    • Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095-2103.
    • (2000) J Clin Oncol , vol.18 , Issue.10 , pp. 2095-2103
    • Shepherd, F.A.1    Dancey, J.2    Ramlau, R.3
  • 61
    • 0034095853 scopus 로고    scopus 로고
    • Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group
    • Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18(12):2354-2362.
    • (2000) J Clin Oncol , vol.18 , Issue.12 , pp. 2354-2362
    • Fossella, F.V.1    Devore, R.2    Kerr, R.N.3
  • 62
    • 33644666521 scopus 로고    scopus 로고
    • Phase III study of secondline chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel
    • Schuette W, Nagel S, Blankenburg T, et al. Phase III study of secondline chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol. 2005;23(33): 8389-8395.
    • (2005) J Clin Oncol , vol.23 , Issue.33 , pp. 8389-8395
    • Schuette, W.1    Nagel, S.2    Blankenburg, T.3
  • 63
    • 33644694366 scopus 로고    scopus 로고
    • Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: A Spanish Lung Cancer Group trial
    • Camps C, Massuti B, Jiménez A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol. 2006 17(3):467-472.
    • (2006) Ann Oncol , vol.17 , Issue.3 , pp. 467-472
    • Camps, C.1    Massuti, B.2    Jiménez, A.3
  • 64
    • 19944430496 scopus 로고    scopus 로고
    • A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study
    • Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer. 2004;91(12):1996-2004.
    • (2004) Br J Cancer , vol.91 , Issue.12 , pp. 1996-2004
    • Gridelli, C.1    Gallo, C.2    di Maio, M.3
  • 65
    • 64649091718 scopus 로고    scopus 로고
    • Meta-analysis of singleagent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer
    • Di Maio M, Chiodini P, Georgoulias V, et al. Meta-analysis of singleagent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(11):1836-1843.
    • (2009) J Clin Oncol , vol.27 , Issue.11 , pp. 1836-1843
    • di Maio, M.1    Chiodini, P.2    Georgoulias, V.3
  • 66
    • 0012381722 scopus 로고    scopus 로고
    • Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)
    • Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 2003;21(12):2237-2246.
    • (2003) J Clin Oncol , vol.21 , Issue.12 , pp. 2237-2246
    • Fukuoka, M.1    Yano, S.2    Giaccone, G.3
  • 67
    • 0142055937 scopus 로고    scopus 로고
    • Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial
    • Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149-2158.
    • (2003) JAMA , vol.290 , Issue.16 , pp. 2149-2158
    • Kris, M.G.1    Natale, R.B.2    Herbst, R.S.3
  • 68
    • 52049125250 scopus 로고    scopus 로고
    • Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer
    • Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol. 2008;26(26):4244-4252.
    • (2008) J Clin Oncol , vol.26 , Issue.26 , pp. 4244-4252
    • Maruyama, R.1    Nishiwaki, Y.2    Tamura, T.3
  • 69
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial
    • Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008 22;372(9652):1809-1818.
    • (2008) Lancet , vol.22-372 , Issue.9652 , pp. 1809-1818
    • Kim, E.S.1    Hirsh, V.2    Mok, T.3    Et al.4
  • 70
    • 27544503230 scopus 로고    scopus 로고
    • Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
    • Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527-1537.
    • (2005) Lancet , vol.366 , Issue.9496 , pp. 1527-1537
    • Thatcher, N.1    Chang, A.2    Parikh, P.3
  • 71
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • Shepherd FA, Rodrigues Pereira J, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-132.
    • (2005) N Engl J Med , vol.353 , Issue.2 , pp. 123-132
    • Shepherd, F.A.1    Rodrigues Pereira, J.2
  • 72
    • 65649132497 scopus 로고    scopus 로고
    • A Phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of Bevacizumab in combination with Erlotinib compared with Erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA)
    • Hainsworth J, Herbst RS. A Phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of Bevacizumab in combination with Erlotinib compared with Erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA). Presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology; November 2008.
    • (2008) Presented At the 2008 Chicago Multidisciplinary Symposium In Thoracic Oncology
    • Hainsworth, J.1    Herbst, R.S.2
  • 73
    • 70349476412 scopus 로고    scopus 로고
    • Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)
    • Suppl; abstract 8009
    • Natale RB, Thongprasert S, Greco FA, et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST). J Clin Oncol. 2009;27:15s (Suppl; abstract 8009).
    • (2009) J Clin Oncol , vol.27
    • Natale, R.B.1    Thongprasert, S.2    Greco, F.A.3
  • 74
    • 69349097838 scopus 로고    scopus 로고
    • Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    • Suppl; abstract 8003
    • Herbst RS, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). J Clin Oncol. 2009;27:18s (Suppl; abstract 8003).
    • (2009) J Clin Oncol , vol.27
    • Herbst, R.S.1    Sun, Y.2    Korfee, S.3
  • 75
    • 70349474058 scopus 로고    scopus 로고
    • Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL)
    • Suppl; abstract 8010
    • De Boer R, Arrieta Ó, Gottfried M, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL). J Clin Oncol. 2009;27:15s (Suppl; abstract 8010).
    • (2009) J Clin Oncol , vol.27
    • de Boer, R.1    Arrieta, O.2    Gottfried, M.3
  • 76
    • 41149147579 scopus 로고    scopus 로고
    • Sorafenib (BAY 43-9006): Review of clinical development
    • Ng R, Chen EX. Sorafenib (BAY 43-9006): review of clinical development. Curr Clin Pharmacol. 2006;1(3):223-228.
    • (2006) Curr Clin Pharmacol , vol.1 , Issue.3 , pp. 223-228
    • Ng, R.1    Chen, E.X.2
  • 78
    • 73949092851 scopus 로고    scopus 로고
    • Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study
    • Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol. 2010;28(1):49-55.
    • (2010) J Clin Oncol , vol.28 , Issue.1 , pp. 49-55
    • Goss, G.D.1    Arnold, A.2    Shepherd, F.A.3
  • 79
    • 70349462997 scopus 로고    scopus 로고
    • The rationale and development of therapeutic insulin-like growth factor axis inhibitors for lung and other cancers
    • Camidge DR, Dziadziuszko R, Hirsch FR. The rationale and development of therapeutic insulin-like growth factor axis inhibitors for lung and other cancers. Clin Lung Cancer. 2009;10(4):262-272.
    • (2009) Clin Lung Cancer , vol.10 , Issue.4 , pp. 262-272
    • Camidge, D.R.1    Dziadziuszko, R.2    Hirsch, F.R.3
  • 80
    • 66349091290 scopus 로고    scopus 로고
    • Phase II study of the antiinsulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer
    • Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the antiinsulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol. 2009;27(15):2516-2522.
    • (2009) J Clin Oncol , vol.27 , Issue.15 , pp. 2516-2522
    • Karp, D.D.1    Paz-Ares, L.G.2    Novello, S.3
  • 81
    • 22044453790 scopus 로고    scopus 로고
    • Erlotinib in lung cancer molecular and clinical predictors of outcome
    • Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer molecular and clinical predictors of outcome.N Engl J Med. 2005;14; 353(2):133-144.
    • (2005) N Engl J Med , vol.14-353 , Issue.2 , pp. 133-144
    • Tsao, M.S.1    Sakurada, A.2    Cutz, J.C.3    Et al.4
  • 82
    • 70349720358 scopus 로고    scopus 로고
    • Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS)
    • Suppl; abstract 8006
    • Fukuoka M, Wu Y, Thongprasert S, et al. Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol. 2009;27:15s (Suppl; abstract 8006).
    • (2009) J Clin Oncol , vol.27
    • Fukuoka, M.1    Wu, Y.2    Thongprasert, S.3
  • 83
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139.
    • (2004) N Engl J Med , vol.350 , Issue.21 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3
  • 84
    • 69949186250 scopus 로고    scopus 로고
    • Screening for epidermal growth factor receptor mutations in lung cancer
    • Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958-967.
    • (2009) N Engl J Med , vol.361 , Issue.10 , pp. 958-967
    • Rosell, R.1    Moran, T.2    Queralt, C.3
  • 85
    • 20044364933 scopus 로고    scopus 로고
    • EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment
    • Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23(4):857-865.
    • (2005) J Clin Oncol , vol.23 , Issue.4 , pp. 857-865
    • Marchetti, A.1    Martella, C.2    Felicioni, L.3
  • 86
    • 28844449401 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials
    • Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005;23(31):8081-8092.
    • (2005) J Clin Oncol , vol.23 , Issue.31 , pp. 8081-8092
    • Bell, D.W.1    Lynch, T.J.2    Haserlat, S.M.3
  • 87
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma
    • Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10): 947-957.
    • (2009) N Engl J Med , vol.361 , Issue.10 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3
  • 88
    • 33846430935 scopus 로고    scopus 로고
    • Squamous cell carcinoma of the lung: Pattern of epidermal growth factor receptor mutation distribution in different populations: A summary
    • Wiwanitkit V. Squamous cell carcinoma of the lung: pattern of epidermal growth factor receptor mutation distribution in different populations: a summary. Lung. 2006;184(5):301-302.
    • (2006) Lung , vol.184 , Issue.5 , pp. 301-302
    • Wiwanitkit, V.1
  • 89
    • 33645805630 scopus 로고    scopus 로고
    • Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas
    • Pham D, Kris MG, Riely GJ, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol. 2006;24(11):1700-1704.
    • (2006) J Clin Oncol , vol.24 , Issue.11 , pp. 1700-1704
    • Pham, D.1    Kris, M.G.2    Riely, G.J.3
  • 90
    • 70349591635 scopus 로고    scopus 로고
    • Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment
    • Jida M, Toyooka S, Mitsudomi T, et al. Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment. Cancer Sci. 2009;100(10):1931-1934.
    • (2009) Cancer Sci , vol.100 , Issue.10 , pp. 1931-1934
    • Jida, M.1    Toyooka, S.2    Mitsudomi, T.3
  • 91
    • 52049090365 scopus 로고    scopus 로고
    • Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
    • Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26(26):4268-4275.
    • (2008) J Clin Oncol , vol.26 , Issue.26 , pp. 4268-4275
    • Zhu, C.Q.1    da Cunha Santos, G.2    Ding, K.3
  • 92
    • 33750962024 scopus 로고    scopus 로고
    • Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
    • Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006;24(31): 5034-5042.
    • (2006) J Clin Oncol , vol.24 , Issue.31 , pp. 5034-5042
    • Hirsch, F.R.1    Varella-Garcia, M.2    Bunn Jr., P.A.3
  • 93
    • 15744372810 scopus 로고    scopus 로고
    • KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
    • Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2(1):e17.
    • PLoS Med , vol.2 , Issue.1
    • Pao, W.1    Wang, T.Y.2    Riely, G.J.3    Et al.4
  • 94
    • 34249810645 scopus 로고    scopus 로고
    • KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
    • Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007;13(10):2890-2896.
    • (2007) Clin Cancer Res , vol.13 , Issue.10 , pp. 2890-2896
    • Massarelli, E.1    Varella-Garcia, M.2    Tang, X.3
  • 95
    • 33846483745 scopus 로고    scopus 로고
    • EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: Retroand prospective observations in non-small-cell lung cancer
    • van Zandwijk N, Mathy A, Boerrigter L, et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retroand prospective observations in non-small-cell lung cancer. Ann Oncol. 2007;18(1):99-103.
    • (2007) Ann Oncol , vol.18 , Issue.1 , pp. 99-103
    • van Zandwijk, N.1    Mathy, A.2    Boerrigter, L.3
  • 96
    • 33751292685 scopus 로고    scopus 로고
    • Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
    • Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006;12:6494-6501.
    • (2006) Clin Cancer Res , vol.12 , pp. 6494-6501
    • Balak, M.N.1    Gong, Y.2    Riely, G.J.3
  • 97
    • 34249075147 scopus 로고    scopus 로고
    • MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    • Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039-1043.
    • (2007) Science , vol.316 , pp. 1039-1043
    • Engelman, J.A.1    Zejnullahu, K.2    Mitsudomi, T.3
  • 98
    • 0027973206 scopus 로고
    • DNA repair. Incisions for excision
    • Hoeijmakers JH, Bootsma D. DNA repair. Incisions for excision. Nature. 1994;371(6499):654-655.
    • (1994) Nature , vol.371 , Issue.6499 , pp. 654-655
    • Hoeijmakers, J.H.1    Bootsma, D.2
  • 99
    • 0034054137 scopus 로고    scopus 로고
    • Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells
    • Li Q, Yu JJ, Mu C, et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res. 2000;20(2A):645-652.
    • (2000) Anticancer Res , vol.20 , Issue.2 A , pp. 645-652
    • Li, Q.1    Yu, J.J.2    Mu, C.3
  • 100
    • 33748435058 scopus 로고    scopus 로고
    • DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
    • Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983-991.
    • (2006) N Engl J Med , vol.355 , Issue.10 , pp. 983-991
    • Olaussen, K.A.1    Dunant, A.2    Fouret, P.3
  • 101
    • 0036890375 scopus 로고    scopus 로고
    • DNA repair and cisplatin resistance in non-small-cell lung cancer
    • Rosell R, Lord RV, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer. 2002;38(3):217-227.
    • (2002) Lung Cancer , vol.38 , Issue.3 , pp. 217-227
    • Rosell, R.1    Lord, R.V.2    Taron, M.3    Reguart, N.4
  • 102
    • 34447573875 scopus 로고    scopus 로고
    • Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer
    • Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007;25(19):2747-2754.
    • (2007) J Clin Oncol , vol.25 , Issue.19 , pp. 2747-2754
    • Cobo, M.1    Isla, D.2    Massuti, B.3
  • 103
    • 33750579074 scopus 로고    scopus 로고
    • RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer
    • Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol. 2006;24(29):4731-4737.
    • (2006) J Clin Oncol , vol.24 , Issue.29 , pp. 4731-4737
    • Bepler, G.1    Kusmartseva, I.2    Sharma, S.3
  • 104
    • 34447567414 scopus 로고    scopus 로고
    • Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer
    • Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007;25(19):2741-2746.
    • (2007) J Clin Oncol , vol.25 , Issue.19 , pp. 2741-2746
    • Simon, G.1    Sharma, A.2    Li, X.3
  • 105
    • 33847364471 scopus 로고    scopus 로고
    • Pemetrexed: Biochemical and cellular pharmacology, mechanisms, and clinical applications
    • Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther. 2007;6(2):404-417.
    • (2007) Mol Cancer Ther , vol.6 , Issue.2 , pp. 404-417
    • Chattopadhyay, S.1    Moran, R.G.2    Goldman, I.D.3
  • 106
    • 33749587054 scopus 로고    scopus 로고
    • Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase
    • Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006;107(7): 1589-1596.
    • (2006) Cancer , vol.107 , Issue.7 , pp. 1589-1596
    • Ceppi, P.1    Volante, M.2    Saviozzi, S.3
  • 107
    • 34547638047 scopus 로고    scopus 로고
    • Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
    • Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561-566.
    • (2007) Nature , vol.448 , Issue.7153 , pp. 561-566
    • Soda, M.1    Choi, Y.L.2    Enomoto, M.3
  • 108
    • 75749088881 scopus 로고    scopus 로고
    • Clinical activity of the oral ALK and MET inhibitor PF-02341066 in non-small lung cancer (NSCLC) with EML4-ALK translocations
    • Suppl 1; abstract A6.4
    • Shaw AT, Costa DB, Iafrate AJ. Clinical activity of the oral ALK and MET inhibitor PF-02341066 in non-small lung cancer (NSCLC) with EML4-ALK translocations. J Thorac Oncol. 2009;4:S305 (Suppl 1; abstract A6.4).
    • (2009) J Thorac Oncol , vol.4
    • Shaw, A.T.1    Costa, D.B.2    Iafrate, A.J.3
  • 109
    • 37549060017 scopus 로고    scopus 로고
    • EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers
    • Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008 Jan; 3(1):13-17.
    • (2008) J Thorac Oncol , vol.3 , Issue.1 , pp. 13-17
    • Inamura, K.1    Takeuchi, K.2    Togashi, Y.3
  • 110
    • 65249095599 scopus 로고    scopus 로고
    • The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS
    • Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115(8):1723-1733.
    • (2009) Cancer , vol.115 , Issue.8 , pp. 1723-1733
    • Wong, D.W.1    Leung, E.L.2    So, K.K.3
  • 111
    • 40149109522 scopus 로고    scopus 로고
    • EML4-ALK fusion lung cancer: A rare acquired event
    • Perner S, Wagner PL, Demichelis F, et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia. 2008;10(3):298-302.
    • (2008) Neoplasia , vol.10 , Issue.3 , pp. 298-302
    • Perner, S.1    Wagner, P.L.2    Demichelis, F.3
  • 112
    • 70349336416 scopus 로고    scopus 로고
    • Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
    • Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247-4253.
    • (2009) J Clin Oncol , vol.27 , Issue.26 , pp. 4247-4253
    • Shaw, A.T.1    Yeap, B.Y.2    Mino-Kenudson, M.3
  • 113
    • 77649109910 scopus 로고    scopus 로고
    • Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program
    • Suppl; abstract 8024
    • Kim ES, Herbst RS, Lee JJ, et al. Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program. J Clin Oncol. 2009;27:15s(Suppl; abstract 8024).
    • (2009) J Clin Oncol , vol.27
    • Kim, E.S.1    Herbst, R.S.2    Lee, J.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.